Skip to main content
. Author manuscript; available in PMC: 2017 Oct 20.
Published in final edited form as: Mol Cell. 2016 Oct 20;64(2):416–430. doi: 10.1016/j.molcel.2016.09.034

Figure 6. Validation of RBRs in L1TD1 and TET2.

Figure 6

(A) Primary sequence and known domains for L1TD1 (top); smoothed residue-level RBR-ID score plotted along the primary sequence (middle); and scheme of epitope-tagged WT and RBR-deleted (ΔRBR) constructs used for validation (bottom).

(B) PAR-CLIP of transiently expressed WT and ΔRBR L1TD1 in HEK293 cells. Autoradiography for 32P-labeled RNA (top) and control western blot (bottom).

(C) PAR-CLIP for WT L1TD1 with and without treatment with RNase A (top) and control western blot (bottom).

(D) Primary sequence and known domains for TET2 (top); smoothed residue-level RBR-ID score plotted along the primary sequence (middle); and scheme of epitope-tagged catalytic domain fragment (CD) and RBR-deleted (CDΔRBR) constructs used for validation (bottom).

(E) PAR-CLIP of transiently expressed TET2-CD and TET2-CDΔRBR in HEK293 cells. Autoradiography for 32P-labeled RNA (top) and control western blot (bottom).

(F) PAR-CLIP for TET2 CD with and without treatment with RNase A (top) and control western blot (bottom).

See also Table S8 and Figure S6.